Ellipta Programme

GlaxoSmithKline (GSK) embarked on the development and global rollout of the Ellipta inhaler—a next-generation respiratory device requiring a complex, multi-phase capital investment programme. The challenge was to deliver new and refurbished manufacturing and laboratory facilities across multiple international sites, ensuring alignment with stringent regulatory standards and market launch timelines. Coordinating diverse stakeholders and maintaining control over costs, schedules, and risks across various geographies added to the complexity of the programme.

G&T provided Cost Management and Programme & Project Controls services throughout the Ellipta Programme. Beginning with Phase 1, we implemented robust project controls to manage over £500 million in capital expenditure, ensuring that launch dates were met across multiple global markets. Subsequent phases involved the delivery of new build and refurbished manufacturing and laboratory spaces, assembly and packing lines, blending suites, and dry powder filling lines. Our role encompassed integrated schedule management, risk and change management, and the preparation of detailed progress reports, facilitating informed decision-making and enhancing confidence in fast-paced investment decisions.

The Ellipta Programme successfully established a global manufacturing network capable of producing up to 120 million inhaler devices annually. G&T's strategic oversight and meticulous project controls ensured that each phase was delivered on time and within budget, aligning with GSK's global supply chain strategy. The programme's success not only supported the commercial launch of the Ellipta inhaler but also reinforced G&T's reputation for managing complex, multi-site pharmaceutical projects with precision and efficiency.